Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,treasuryStock,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,accountsPayable,changeToLiabilities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,currency,esgPopulated,tradeable,market,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,shortName,exchange,dividendDate,epsTrailingTwelveMonths,exchangeDataDelayedBy,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,longBusinessSummary,city,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,HMTXF,-1559697.0,57504100,54436,,-683703,,-683703,519091,0,-664203,-664203,,-2533,,,,0,0,664203,0,-19500,,-683703,-683703,1.0,8694181.0,2485657.0,-1559696.0,1044564.0,925961.0,38128032.0,-49925708.0,1543799.0,537876.0,2485657.0,1543799.0,1726.0,924234.0,386358.0,1391593.0,-761118.0,-175000.0,-42697.0,1673126.0,132303.0,279925.0,322622.0,276.0,3641.0,90400.0,,-1561423.0,en-US,US,EQUITY,False,Delayed Quote,-0.05952482,0.1679 - 0.1679,0.168,0.0,0.0,0,0,finmb_240304994,Other OTC,Hemostemix Inc.,CAD,2935,862,0.0659,0.6460784,0.102 - 0.7,-0.53209996,-0.7601428,0.102,0.7,USD,False,False,us_market,0.1679,1630514818,-0.00010000169,0.1679,0.1679,0.1679,1000,PRE,HEMOSTEMIX INC,PNK,1609286400,-0.161,0,-0.028,0.17216945,-0.004269451,-0.02479796,0.2565438,-0.08864379,-0.34553084,10431862,-5.996428,15,America/New_York,EDT,-14400000,4,0.36,,,0.7,0.102,0.1722,0.2565,2.94k,862,57.5M,,43.79M,15.92%,6.27%,,,,,,,,,,,0.00%,"Dec 29, 2020",,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-482.34%,,,,,,-5.44M,-8.31M,-0.1610,,537.88k,0.01,,,0.37,-0.03,-5.46M,-804.08k,Value,T2P 3H6,Healthcare,"Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, an autologous cell therapy for the treatment of critical limb ischemia, which is in Phase II clinical trial in Canada and the United States. It is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. The company is headquartered in Calgary, Canada.",Calgary,AB,1609372800,Canada,http://www.hemostemix.com,86400,707-7th Avenue SW,Biotechnology,Suite 1150
t-1,HMTXF,-1098697.0,57504100,-266478,,-3989434,,-3989434,-1277531,0,-1275605,-1275605,,-5232,,,,0,0,1275605,0,-2713829,,-3989434,-3989434,1.0,8712132.0,3421775.0,-1098696.0,1044564.0,2323079.0,37893756.0,-49242005.0,1537421.0,257951.0,3421775.0,1537421.0,2002.0,2321076.0,2063125.0,2170370.0,-1005148.0,493298.0,4244398.0,-1916008.0,4280948.0,172006.0,-4072392.0,612.0,17736.0,2819850.0,-529848.0,-1100699.0,en-US,US,EQUITY,False,Delayed Quote,-0.05952482,0.1679 - 0.1679,0.168,0.0,0.0,0,0,finmb_240304994,Other OTC,Hemostemix Inc.,CAD,2935,862,0.0659,0.6460784,0.102 - 0.7,-0.53209996,-0.7601428,0.102,0.7,USD,False,False,us_market,0.1679,1630514818,-0.00010000169,0.1679,0.1679,0.1679,1000,PRE,HEMOSTEMIX INC,PNK,1609286400,-0.161,0,-0.028,0.17216945,-0.004269451,-0.02479796,0.2565438,-0.08864379,-0.34553084,10431862,-5.996428,15,America/New_York,EDT,-14400000,4,0.36,,,0.7,0.102,0.1722,0.2565,2.94k,862,57.5M,,43.79M,15.92%,6.27%,,,,,,,,,,,0.00%,"Dec 29, 2020",,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-482.34%,,,,,,-5.44M,-8.31M,-0.1610,,537.88k,0.01,,,0.37,-0.03,-5.46M,-804.08k,Value,T2P 3H6,Healthcare,"Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, an autologous cell therapy for the treatment of critical limb ischemia, which is in Phase II clinical trial in Canada and the United States. It is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. The company is headquartered in Calgary, Canada.",Calgary,AB,1609372800,Canada,http://www.hemostemix.com,86400,707-7th Avenue SW,Biotechnology,Suite 1150
t-2,HMTXF,-4014283.0,57504100,281510,,-1613525,,-1613525,1168683,0,-1453619,-1453619,,-1176,,,,0,0,1453619,0,-159906,,-1613525,-1613525,1.0,5896742.0,4267695.0,-4014282.0,,253413.0,33629799.0,-45252571.0,1711748.0,85945.0,4267695.0,1711748.0,2614.0,250798.0,164853.0,3207357.0,1018759.0,493298.0,174917.0,-38530.0,191717.0,-338961.0,-513878.0,612.0,55348.0,63458.0,-16800.0,-4016897.0,en-US,US,EQUITY,False,Delayed Quote,-0.05952482,0.1679 - 0.1679,0.168,0.0,0.0,0,0,finmb_240304994,Other OTC,Hemostemix Inc.,CAD,2935,862,0.0659,0.6460784,0.102 - 0.7,-0.53209996,-0.7601428,0.102,0.7,USD,False,False,us_market,0.1679,1630514818,-0.00010000169,0.1679,0.1679,0.1679,1000,PRE,HEMOSTEMIX INC,PNK,1609286400,-0.161,0,-0.028,0.17216945,-0.004269451,-0.02479796,0.2565438,-0.08864379,-0.34553084,10431862,-5.996428,15,America/New_York,EDT,-14400000,4,0.36,,,0.7,0.102,0.1722,0.2565,2.94k,862,57.5M,,43.79M,15.92%,6.27%,,,,,,,,,,,0.00%,"Dec 29, 2020",,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-482.34%,,,,,,-5.44M,-8.31M,-0.1610,,537.88k,0.01,,,0.37,-0.03,-5.46M,-804.08k,Value,T2P 3H6,Healthcare,"Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, an autologous cell therapy for the treatment of critical limb ischemia, which is in Phase II clinical trial in Canada and the United States. It is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. The company is headquartered in Calgary, Canada.",Calgary,AB,1609372800,Canada,http://www.hemostemix.com,86400,707-7th Avenue SW,Biotechnology,Suite 1150
t-3,HMTXF,-2638409.0,57504100,603772,,-2025336,,-2025336,1438422,0,-2046971,-2046971,,-52465,,,,0,0,2046971,0,21635,,-2025336,-2025336,1.0,5454221.0,3248212.0,-2638408.0,,609804.0,33490332.0,-43639046.0,2056085.0,424906.0,3248212.0,2056085.0,3226.0,606577.0,181671.0,2188599.0,809925.0,-467712.0,1182611.0,-40208.0,1810534.0,-15193.0,-1197804.0,612.0,-101467.0,158670.0,-160211.0,-2641635.0,en-US,US,EQUITY,False,Delayed Quote,-0.05952482,0.1679 - 0.1679,0.168,0.0,0.0,0,0,finmb_240304994,Other OTC,Hemostemix Inc.,CAD,2935,862,0.0659,0.6460784,0.102 - 0.7,-0.53209996,-0.7601428,0.102,0.7,USD,False,False,us_market,0.1679,1630514818,-0.00010000169,0.1679,0.1679,0.1679,1000,PRE,HEMOSTEMIX INC,PNK,1609286400,-0.161,0,-0.028,0.17216945,-0.004269451,-0.02479796,0.2565438,-0.08864379,-0.34553084,10431862,-5.996428,15,America/New_York,EDT,-14400000,4,0.36,,,0.7,0.102,0.1722,0.2565,2.94k,862,57.5M,,43.79M,15.92%,6.27%,,,,,,,,,,,0.00%,"Dec 29, 2020",,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-482.34%,,,,,,-5.44M,-8.31M,-0.1610,,537.88k,0.01,,,0.37,-0.03,-5.46M,-804.08k,Value,T2P 3H6,Healthcare,"Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, an autologous cell therapy for the treatment of critical limb ischemia, which is in Phase II clinical trial in Canada and the United States. It is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. The company is headquartered in Calgary, Canada.",Calgary,AB,1609372800,Canada,http://www.hemostemix.com,86400,707-7th Avenue SW,Biotechnology,Suite 1150
